Is obesity a prognostic factor for acute myeloid leukemia outcome?
Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Meir Wetzler, Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Sheila N.J. Sait(Roswell Park Comprehensive Cancer Center), Maria R. Baer(University of Maryland, Baltimore), Andrea S. Licht(Roswell Park Comprehensive Cancer Center), Maurice Barcos(Roswell Park Comprehensive Cancer Center), Laurie Ford(Roswell Park Comprehensive Cancer Center), AnneMarie W. Block(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Andrew Hyland(Roswell Park Comprehensive Cancer Center)
Cited by 35
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2017|655